Innovation Pharmaceuticals Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was USD 3.17 million compared to USD 7.04 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.003 USD | +50.00% | -28.57% | -38.78% |
Feb. 01 | Innovation Pharmaceuticals Inc. Announces Resignation of Board Members | CI |
2023 | Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement | CI |
1st Jan change | Capi. | |
---|---|---|
-38.78% | 1.59M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IPIX Stock
- News Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023